RAPT Therapeutics (RAPT) Announced Proposed Offering of $125M Worth of Shares
- Wall St slips as higher yields offset upbeat corporate earnings
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- Boeing reports first revenue drop in 7 quarters as deliveries decline
- Oil prices fall as U.S. business activity cools, concerns over Middle East ease
- Yen on the brink, but Tesla pulls back
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Hasbro (HAS) brand strength sees earnings top expectations
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
RAPT Therapeutics (RAPT) Prices 3.79M Common Stock Offering at $33/Sh
June 16, 2021 6:17 AM EDTRAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced the pricing of its previously announced underwritten public offering of 3,787,879 shares of its common stock at a price to the public of $33.00 per share. All of the shares of common stock are being offered by RAPT. Gross proceeds to RAPT from the offering are expected to be approximately $125 million,... More
RAPT Therapeutics (RAPT) Adds to Intra-Day Gains Despite Stock Offering; Last Up 23%
June 14, 2021 5:46 PM EDTRAPT Therapeutics (NASDAQ: RAPT) is adding to its intra-day gains despite announcing a $125 million share stock offering.
Shares are up 22.5% after-hours after gaining 115% intra-day on positive topline results from its randomized placebo-controlled Phase 1b clinical trial of RPT193 as monotherapy in 31 patients with moderate-to-severe atopic dermatitis (AD).
... MoreRapt Therapeutics (RAPT) PT Raised to $65 at Wells Fargo
June 14, 2021 2:30 PM EDTWells Fargo analyst Yanan Zhu raised the price target on Rapt Therapeutics (NASDAQ: RAPT) to $65.00 (from $30.00) while maintaining a Overweight rating.
... MoreRapt Therapeutics (RAPT) PT Raised to $72 at Roth Capital, Following Clinical Business Update
June 14, 2021 2:21 PM EDTRoth Capital analyst Zegbeh Jallah raised the price target on Rapt Therapeutics (NASDAQ: RAPT) to $72.00 (from $38.00) while maintaining a Buy rating.
... MoreRapt Therapeutics (RAPT) PT Raised to 'Street High' $71 at Cantor Fitzgerald
June 14, 2021 11:23 AM EDTCantor Fitzgerald analyst Alethia Young raised the price target on Rapt Therapeutics (NASDAQ: RAPT) to a "Street High" $71.00 (from $51.00) while maintaining an Overweight rating following today's data.
... MoreIncreasing unusual option volume: RAPT OR CCXI PARR ITB DS CRSR WEN TD
June 14, 2021 10:21 AM EDTIncreasing unusual option volume: RAPT OR CCXI PARR ITB DS CRSR WEN TD
... MorePre-Open Stock Movers 06/14: (RAPT) (CRSR) (RIOT) Higher; (ATXI) (RIDE) (RACE) Lower (more...)
June 14, 2021 9:27 AM EDTPre-Open Stock Movers:
RAPT Therapeutics (NASDAQ: RAPT) 89% HIGHER; announced positive topline results from its randomized placebo-controlled Phase 1b clinical trial of RPT193 as monotherapy in 31 patients with moderate-to-severe atopic dermatitis (AD).
Avenue Therapeutics, Inc. (NASDAQ: ATXI) 49.4% LOWER; announced that it has received a second Complete Response Letter from the U.S. Food and Drug Administration regarding its New Drug Application seeking... More
RAPT Therapeutics (RAPT) Surges 70% on Positive Early Trial Results
June 14, 2021 8:41 AM EDTRAPT Therapeutics (NASDAQ: RAPT) surges 70% in pre-open trading after the company announced positive topline results from its randomized placebo-controlled Phase 1b clinical trial of RPT193 as monotherapy in 31 patients with moderate-to-severe atopic dermatitis (AD).
... MoreRAPT Therapeutics (RAPT) Reports Positive Topline Results from Phase 1b Trial of RPT193 Monotherapy in Atopic Dermatitis
June 14, 2021 8:00 AM EDTRAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced positive topline results from its randomized placebo-controlled Phase 1b clinical trial of RPT193 as monotherapy in 31 patients with moderate-to-severe atopic dermatitis (AD). After four weeks of treatment, patients with moderate-to-severe AD who received RPT193 showed a 36.3% improvement from baseline in the Eczema Area and Severity Index (EASI) score, a standard measure of disease severity, compared to 17.0% in the placebo group.... More